Literature DB >> 18685377

Is there a common mechanism linking muscle wasting in various disease types?

Michael J Tisdale.   

Abstract

PURPOSE OF REVIEW: There have been a number of recent developments in our understanding of the cellular mechanisms leading to muscle atrophy, which are likely to be of major importance in the design of therapeutic agents. RECENT
FINDINGS: Muscle atrophy in a range of conditions is thought to be due to an increased expression of the ubiquitin-proteasome proteolytic pathway. The main transcription factors involved in muscle atrophy are nuclear factor-kappaB and the forkhead type transcription factors, as determined from experiments with transgenic mice. Catabolic agents such as cytokines, proteolysis-inducing factor and angiotensin II induce activation of nuclear factor-kappaB through an increase in reactive oxygen species, causing an increased gene expression of proteasome subunits and the ubiquitin ligase MuRF1. Glucocorticoids cause activation of forkhead type transcription factors possibly through an increase in expression of myostatin, which leads to an increased expression of the E3 ligase atrogin-1/MAFbx and cathepsin L. Forkhead type transcription factors is regulated by its state of phosphorylation induced by Akt, while activation of nuclear factor-kappaB requires reactive oxygen species and activation of the dsRNA-dependent protein kinase. Activation of dsRNA-dependent protein kinase also inhibits translational initiation of protein synthesis through phosphorylation of eukaryotic initiation factor 2 on the alpha-subunit.
SUMMARY: These results suggest a common mechanism leading to muscle atrophy, which has important implications in the clinical treatment of wasting diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18685377     DOI: 10.1097/SPC.0b013e3282f35238

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  12 in total

1.  The isolated muscle fibre as a model of disuse atrophy: characterization using PhAct, a method to quantify f-actin.

Authors:  William J Duddy; Tatiana Cohen; Stephanie Duguez; Terence A Partridge
Journal:  Exp Cell Res       Date:  2011-05-20       Impact factor: 3.905

2.  Of Greek heroes, wiggling worms, mighty mice, and old body builders.

Authors:  Luigi Ferrucci; Rafa de Cabo; Nicolas D Knuth; Stephanie Studenski
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-11-23       Impact factor: 6.053

3.  Out-FOX(O)ing proteolysis in sepsis.

Authors:  Stuart M Phillips
Journal:  J Physiol       Date:  2010-04-15       Impact factor: 5.182

Review 4.  The therapeutic potential of IGF-I in skeletal muscle repair.

Authors:  Yao-Hua Song; Jenny L Song; Patrice Delafontaine; Michael P Godard
Journal:  Trends Endocrinol Metab       Date:  2013-04-27       Impact factor: 12.015

Review 5.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

6.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

7.  An inhibitor of eIF2 activity in the sRNA pool of eukaryotic cells.

Authors:  Michael Centrella; David L Porter; Thomas L McCarthy
Journal:  Gene       Date:  2011-05-27       Impact factor: 3.688

8.  Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide.

Authors:  Steven T Russell; Michael J Tisdale
Journal:  Mol Cell Biochem       Date:  2009-04-30       Impact factor: 3.396

Review 9.  MicroRNAs in skeletal muscle: their role and regulation in development, disease and function.

Authors:  Isabelle Güller; Aaron P Russell
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

10.  Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.

Authors:  Suhrad G Banugaria; Sean N Prater; Judeth K McGann; Jonathan D Feldman; Jesse A Tannenbaum; Carrie Bailey; Renuka Gera; Robert L Conway; David Viskochil; Joyce A Kobori; Amy S Rosenberg; Priya S Kishnani
Journal:  Genet Med       Date:  2012-10-11       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.